September 19, 2014 9:07 PM ET

Pharmaceuticals

Company Overview of Shire Orphan Therapies GmbH

Company Overview

Shire Orphan Therapies GmbH is engaged in the discovery, development, and commercialization of peptide-based drugs for disease indications that have limited or no treatment options. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema in Germany, Austria, Spain, Greece, Denmark, Luxemburg, and the United Kingdom; and through named patient programs in France, Italy, Norway, and Belgium. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related macular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor ant...

Friedrichstrasse 149

Berlin,  10117

Germany

Founded in 1994

65 Employees

Phone:

49 30 206 582 0

Fax:

49 30 206 582 100

Key Executives for Shire Orphan Therapies GmbH

Shire Orphan Therapies GmbH does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
axxonis Pharma AG Europe
Allergopharma GmbH & Co. KG Europe
Heumann Pharma GmbH & Co. Generica KG Europe
Pharmacia GmbH Europe
Dermapharm AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Shire Orphan Therapies GmbH, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.